Fundraising Fox
Curi Bio
Founded 2015 · 56 employees on LinkedIn · 1 known investors
Find your way into Curi Bio
Curi Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency. It serves pharmaceutical and biotech R&D teams working on drug discovery.
Founders & leadership
Curi Bio was founded in 2015 by Elliot Fisher.
Investors · 1
How we know: Dynamk Capital's portfolio page · a partner's Signal profile · Not right? Tell us
Funding
SEC filings, press & company announcements$10M disclosed across 1 of 4 rounds · 2021–2025
- $10MSeries BDec 2025 · 2 sourcesSource ↗
- Undisclosed amountSeries ADec 2021Source ↗
- Undisclosed amountSeries AMar 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Non-dilutive funding · 14 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $324.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $275.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $252.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $252.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $221.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $214K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Curi Bio do?
- Curi Bio provides a preclinical drug development platform combining 3D human tissue models of disease (cardiac and skeletal muscle), biosystems for functional analysis, and AI/ML-based insights to assess drug safety, efficacy, and potency. It serves pharmaceutical and biotech R&D teams working on drug discovery.
- Who founded Curi Bio?
- Curi Bio was founded by Elliot Fisher in 2015.
- Who are Curi Bio's investors?
- Curi Bio's investors include Dynamk Capital.
- How much funding has Curi Bio raised?
- Curi Bio has disclosed $10M raised across 1 of its 4 known rounds.